SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...
Lucentis (ranibizumab) is a prescription drug that’s used for eye conditions such as macular edema. Lucentis comes as a liquid solution that’s given by injection into the eye. Lucentis is prescribed ...
Ranibizumab, in combination with prompt verteporfin photodynamic therapy, is more effective in treating polypoidal choroidal vasculopathy compared with ranibizumab monotherapy, according to a study ...
The first-of-its-kind port delivery system with ranibizumab serves as the first wet age-related macular degeneration (AMD) treatment in 15 years to provide an alternative to frequent eye injections.
Please provide your email address to receive an email when new articles are posted on . The Port Delivery System with ranibizumab was noninferior and had similar efficacy to monthly ranibizumab ...
Coherus BioSciences on Oct. 3 plans to debut Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Roche’s Lucentis (ranibizumab injection) for all approved indications. An anti-VEGF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results